Rapport Therapeutics Raises More Than $400 Million Through Stock, Notes, and Private Placement Offerings
Rapport Therapeutics (RAPP) raised over $400M through stock, notes, and private placement offerings on Oct 30, 2026. The company secured $215.7M from a stock offering at $21 per share, $166.8M from convertible notes, and $30M from a private placement. Proceeds will support clinical trials, R&D, and general corporate purposes.
How this was made
The 30-second read
Why it matters
The capital raise provides significant funding for clinical trials and R&D, but introduces dilution risk.
Market read
First‑report of a large financing event that could move RAPP's share price today.
What to watch
Potential strategic partnerships or licensing deals that may arise from the new cash runway.
Background
Rapport Therapeutics closed a series of financings on Oct. 30, 2026, raising over $400 million through a public stock and pre‑funded warrant offering, $172.5 million of convertible notes, and a $30 million private placement.
Ticker impact
Rapport Therapeutics announced a $400M+ capital raise via a public stock offering, convertible notes and a private placement.
likely modest downside as the market prices in dilution from the new shares and notes
First‑report of a sizable raise; traders may sell on dilution risk, though funding could support future milestones.
Market effects
Biotech financing may signal increased R&D activity and could encourage similar capital raises in the sector.
US biotech and pharma stocks could see short‑term pressure from dilution concerns.
Limited to companies with comparable clinical‑trial funding needs.
Counterpoint
The raise could fund breakthrough trials that boost long‑term valuation, outweighing short‑term dilution.
Key entities
- companyRapport Therapeutics
US‑listed biotech firm (ticker RAPP) raising capital for clinical development.